Dr. Jack Regan, CEO and Founder of LexaGene gives an update to BioPub Investment group on January 26, 2021.
Learn more about new FDA antimicrobial stewardship guidance impacts the world of veterinary medicine in the coming years and how LexaGene’s MiQLab™ offers a solution.
Learn more about the MiQLab solution offering in-clinic point-of-care veterinary diagnostic testing in ~2 hours addressing more than 50 percent of companion animal vet visits and increasing satisfaction.
LexaGene’s MiQLab has direct benefits for veterinary clinics. Using LexaGene’s proven point-of-care diagnostics for evidence-based treatment of common bacterial infections found in companion animals may also result in cost savings.
The global bioburden testing market for bio-pharma contamination is approximately $10B, with over 350M tests run annually. LexaGene provides early detection for mycoplasma, aiding in validating product quality for biopharmaceutical manufacturers.